SG11202001014WA - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant - Google Patents
Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplantInfo
- Publication number
- SG11202001014WA SG11202001014WA SG11202001014WA SG11202001014WA SG11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA
- Authority
- SG
- Singapore
- Prior art keywords
- veno
- versus
- treating
- methods
- stem cell
- Prior art date
Links
- 208000017850 Diffuse alveolar hemorrhage Diseases 0.000 title 1
- 208000009329 Graft vs Host Disease Diseases 0.000 title 1
- 208000012346 Venoocclusive disease Diseases 0.000 title 1
- 208000024908 graft versus host disease Diseases 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545864P | 2017-08-15 | 2017-08-15 | |
| US201762574690P | 2017-10-19 | 2017-10-19 | |
| US201862630756P | 2018-02-14 | 2018-02-14 | |
| US201862637281P | 2018-03-01 | 2018-03-01 | |
| PCT/US2018/046690 WO2019036460A1 (en) | 2017-08-15 | 2018-08-14 | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001014WA true SG11202001014WA (en) | 2020-03-30 |
Family
ID=65362042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001014WA SG11202001014WA (en) | 2017-08-15 | 2018-08-14 | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11013772B2 (en) |
| EP (1) | EP3668531A4 (en) |
| JP (2) | JP2020531452A (en) |
| KR (2) | KR20240105500A (en) |
| CN (3) | CN111278449A (en) |
| AU (1) | AU2018318982A1 (en) |
| BR (1) | BR112020003207A2 (en) |
| CA (1) | CA3072940A1 (en) |
| CL (3) | CL2020000384A1 (en) |
| GE (1) | GEP20237541B (en) |
| IL (1) | IL272674B1 (en) |
| JO (1) | JOP20200021A1 (en) |
| MA (1) | MA49915A (en) |
| MX (1) | MX2020001728A (en) |
| PH (1) | PH12020500276A1 (en) |
| SG (1) | SG11202001014WA (en) |
| TW (2) | TWI818919B (en) |
| WO (1) | WO2019036460A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| KR20220104201A (en) * | 2019-11-26 | 2022-07-26 | 오메로스 코포레이션 | Methods of treating and/or preventing idiopathic pneumonia syndrome (IPS) and/or capillary leakage syndrome (CLS) and/or engraftment syndrome (ES) and/or fluid overload (FO) associated with hematopoietic stem cell transplantation |
| CA3159167A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US12030853B2 (en) | 2019-12-04 | 2024-07-09 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP2023504543A (en) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | MASP-2 inhibitors and methods of use |
| CN113057142B (en) * | 2021-03-30 | 2022-12-09 | 四川大学华西医院 | Method for constructing intraretinal and/or subretinal fibrosis animal model |
| IL313331A (en) | 2021-12-10 | 2024-08-01 | Omeros Corp | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| CN114532982A (en) * | 2022-01-12 | 2022-05-27 | 高谋 | System for evaluating complement activation regulation effect of stem cell system transplantation |
| CN114686585B (en) * | 2022-04-01 | 2023-06-30 | 中国人民解放军总医院 | Application of TMEM65 in early warning and/or treating altitude sickness |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (en) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | Tissue-friendly collagen and its manufacturing method |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE115999T1 (en) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | RIBOZYMES. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| JPH10510540A (en) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| EP1200127B1 (en) | 1999-07-21 | 2008-06-25 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| EP1496835A4 (en) | 2002-02-01 | 2006-10-18 | Omeros Corp | Compositions and methods for systemic inhibition of cartilage degradation |
| ES2601143T3 (en) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom. |
| ES2629344T3 (en) | 2003-05-12 | 2017-08-08 | Helion Biotech Aps | Antibodies against MASP-2 |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| JP2008540385A (en) * | 2005-05-06 | 2008-11-20 | ラボラトワール セローノ ソシエテ アノニム | Use of cell surface recognition molecules containing immunoglobulin domains to treat disease |
| CA2804998C (en) * | 2010-07-21 | 2018-11-13 | Eastern Virginia Medical School | Peptide compounds to regulate the complement system |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| CN107011443B (en) | 2011-05-04 | 2021-04-30 | 奥默罗斯公司 | Compositions for inhibiting MASP-2 dependent complement activation |
| EP2948480A4 (en) * | 2013-01-23 | 2016-12-07 | Musc Found For Res Dev | Targeting constructs based on natural antibodies and uses thereof |
| ES2829913T3 (en) * | 2013-10-17 | 2021-06-02 | Omeros Corp | Treatment procedures for conditions associated with MASP-2-dependent complement activation |
| EP3151845A4 (en) | 2014-06-05 | 2018-01-17 | The Regents of the University of Colorado, a body corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| EP3302519B1 (en) * | 2015-06-08 | 2021-12-01 | Volution Immuno Pharmaceuticals SA | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| UA124094C2 (en) * | 2015-11-09 | 2021-07-21 | Омерос Корпорейшн | Methods for treating conditions associated with masp-2 dependent complement activation |
-
2018
- 2018-08-13 TW TW107128182A patent/TWI818919B/en active
- 2018-08-13 TW TW112136719A patent/TW202402809A/en unknown
- 2018-08-14 KR KR1020247021113A patent/KR20240105500A/en unknown
- 2018-08-14 KR KR1020207006893A patent/KR102679441B1/en active IP Right Grant
- 2018-08-14 AU AU2018318982A patent/AU2018318982A1/en active Pending
- 2018-08-14 WO PCT/US2018/046690 patent/WO2019036460A1/en active Application Filing
- 2018-08-14 MX MX2020001728A patent/MX2020001728A/en unknown
- 2018-08-14 MA MA049915A patent/MA49915A/en unknown
- 2018-08-14 JO JOP/2020/0021A patent/JOP20200021A1/en unknown
- 2018-08-14 EP EP18845831.9A patent/EP3668531A4/en active Pending
- 2018-08-14 CA CA3072940A patent/CA3072940A1/en active Pending
- 2018-08-14 SG SG11202001014WA patent/SG11202001014WA/en unknown
- 2018-08-14 US US16/103,332 patent/US11013772B2/en active Active
- 2018-08-14 GE GEAP201815297A patent/GEP20237541B/en unknown
- 2018-08-14 CN CN201880052958.1A patent/CN111278449A/en active Pending
- 2018-08-14 JP JP2020508563A patent/JP2020531452A/en active Pending
- 2018-08-14 CN CN202410427006.0A patent/CN118436776A/en active Pending
- 2018-08-14 CN CN202410427005.6A patent/CN118634322A/en active Pending
- 2018-08-14 BR BR112020003207-7A patent/BR112020003207A2/en unknown
- 2018-08-14 IL IL272674A patent/IL272674B1/en unknown
-
2020
- 2020-02-06 PH PH12020500276A patent/PH12020500276A1/en unknown
- 2020-02-14 CL CL2020000384A patent/CL2020000384A1/en unknown
-
2021
- 2021-04-09 US US17/226,987 patent/US11896621B2/en active Active
-
2022
- 2022-01-25 CL CL2022000194A patent/CL2022000194A1/en unknown
- 2022-01-25 CL CL2022000195A patent/CL2022000195A1/en unknown
-
2023
- 2023-06-21 JP JP2023101662A patent/JP2023123627A/en active Pending
- 2023-12-06 US US18/531,118 patent/US20240293465A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202001014WA (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
| HK1252821A1 (en) | Compositions and methods for treating patients with rtk mutant cells | |
| IL258865A (en) | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 | |
| SG11202005815UA (en) | Bioreactor and related methods | |
| EP3701041A4 (en) | Methods and compositions for treating diseases associated with exhausted t cells | |
| EP3334820C0 (en) | Induced extended pluripotent stem cells, methods of making and using | |
| EP3331582A4 (en) | Methods and compositions for treating cells for transplant | |
| PL3145517T3 (en) | Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same | |
| EP3138399C0 (en) | Composition for organ, tissue, or cell transplantation, kit, and transplantation method | |
| PT3551748T (en) | Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof | |
| HK1258528A1 (en) | Methods and compositions for stem cell transplantation | |
| SG11201706090SA (en) | Cell culturing method and kit | |
| SG11202004935UA (en) | Cell culture methods | |
| IL263341A (en) | Stem cell material, compositions, and methods of use | |
| IL273311A (en) | Biomaterial comprising adipose-derived stem cells and method for producing the same | |
| IL249376B (en) | Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists | |
| HK1258782A1 (en) | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation | |
| EP3139913A4 (en) | Methods and compositions for non-cytotoxic stem cell transplantation | |
| IL277878A (en) | Compositions and methods for stem cell transplant | |
| PL3535511T3 (en) | Reduction of microbiological growth in pipes | |
| IL273258A (en) | Biomaterial comprising adipose-derived stem cells and method for producing the same | |
| EP3201337A4 (en) | Methods and compositions for use of non-coding rna in cell culturing and selection | |
| IL270880A (en) | Cell culture methods | |
| IL256093B (en) | Method for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof | |
| IL255664A0 (en) | Hematopoietic stem cells with improved properties |